SCHEMBL10171024

SCHEMBL10171024

O=c1c2ccc(Br)cc2[nH]c2ccc(Br)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.53
LMNA P02545 3/20 0.51
HPGD P15428 2/20 0.51
CDK9 P50750 2/20 0.48
CDK5 Q00535 2/20 0.48
CAMK2A Q9UQM7 2/20 0.48
METAP2 P50579 1/20 0.48
CHEK1 O14757 1/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
ABL1 P00519 1/20 0.48
NTRK1 P04629 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
MET P08581 1/20 0.48
PDGFRB P09619 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4653063 0.92 HSD17B10 (0.56) HSD17B10LMNAHPGDCDK9CDK5
SCHEMBL30933343 0.92 HSD17B10 (0.59) HSD17B10LMNAHPGDCDK9CDK5
SCHEMBL14543828 0.92 HSD17B10 (0.59) HSD17B10LMNAHPGDCDK9CDK5
SCHEMBL9709050 0.87 GAA (0.67) LMNAHPGDCDK9CDK5CAMK2A
SCHEMBL3854826 0.87 ALDH1A1 (0.67) HSD17B10LMNAHPGDCDK9CDK5
SCHEMBL30982031 0.87 ALDH1A1 (0.67) HSD17B10LMNAHPGDCDK9CDK5
SCHEMBL7669097 0.84 ABCG2 (0.68) HSD17B10HPGDPDGFRBFLT3GSK3B
SCHEMBL29764121 0.84 CHUK (0.61) LMNAHPGDCDK9CDK5CAMK2A
SCHEMBL16552984 0.84 CHUK (0.61) LMNAHPGDCDK9CDK5CAMK2A
SCHEMBL13933196 0.81 KMT2A (0.67) HSD17B10LMNAHPGDCDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150554-B2 Fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-9150554-B2 Fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-8999967-B2 Tricyclic fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-8999967-B2 Tricyclic fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-07 US disclosed
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-07 US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C HAVCR2, HCCS, LIPC HSD17B10 471/4885LMNA 2669/4885HPGD 1773/4885
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C HAVCR2, HCCS, ZC3HAV1 HSD17B10 533/4885LMNA 2515/4885HPGD 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.